BR Biopharma (NASDAQ:BRBI – Get Free Report) and PennantPark Investment (NASDAQ:PNNT – Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Analyst Ratings
This is a summary of recent recommendations and price targets for BR Biopharma and PennantPark Investment, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BR Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| PennantPark Investment | 1 | 3 | 1 | 0 | 2.00 |
PennantPark Investment has a consensus target price of $5.10, suggesting a potential upside of 38.02%. Given PennantPark Investment’s stronger consensus rating and higher probable upside, analysts plainly believe PennantPark Investment is more favorable than BR Biopharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| BR Biopharma | N/A | N/A | N/A |
| PennantPark Investment | 11.33% | 11.59% | 4.23% |
Insider & Institutional Ownership
26.6% of PennantPark Investment shares are held by institutional investors. 3.0% of PennantPark Investment shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares BR Biopharma and PennantPark Investment”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BR Biopharma | $2.23 billion | 0.06 | $31.36 million | $0.08 | 140.81 |
| PennantPark Investment | $21.50 million | 11.22 | $48.85 million | $0.16 | 23.09 |
PennantPark Investment has lower revenue, but higher earnings than BR Biopharma. PennantPark Investment is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.
Dividends
BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.7%. PennantPark Investment pays an annual dividend of $0.48 per share and has a dividend yield of 13.0%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. PennantPark Investment pays out 300.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. PennantPark Investment has increased its dividend for 1 consecutive years. PennantPark Investment is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Summary
PennantPark Investment beats BR Biopharma on 14 of the 16 factors compared between the two stocks.
About BR Biopharma
BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.
About PennantPark Investment
PennantPark Investment Corporation, a business development company is a private equity fund specializes in direct and mezzanine investments in middle market companies. It invests in the form of mezzanine debt, senior secured loans, and equity investments. The fund typically invests in buildings and real estate, hotels, gaming and leisure, technology, telecommunications, transportation, information technology services, electronics, healthcare & pharmaceuticals, education and childcare, financial services, printing and publishing, consumer products, business services, energy & Related Services and utilities, distribution, oil and gas, media, environmental services, aerospace and defense, building materials, capital equipment, chemicals, plastics, & rubber, food & beverage, wholesale, manufacturing and basic industries and retail. It invests in equity securities and debt transactions through preferred stock, common stock, warrants, options, senior secured debt, subordinated debt, subordinated loans, first lien debt, mezzanine loans, and distressed debt securities and private equity co-investments. It seeks to invest in companies based in the United States. The fund seeks to invest between $10 million and $100 million cross the capital structure (senior secured loans, subordinated debt, and other investments) in its portfolio companies with EBITDA between $10 to $50 million. Its mezzanine loans, senior secured loans, and other investments in its portfolio companies are between $15 million and $50 million. The fund may also make non-control equity and debt investments.
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
